Opioid Crisis
Nutriband CEO Discusses AVERSA Technology's Role in Addressing Opioid Crisis on Podcast
Nutriband Inc. CEO Gareth Sheridan highlighted the company's AVERSA abuse-deterrent transdermal technology on a podcast, emphasizing its potential to reduce misuse of high-risk drugs like fentanyl while maintaining patient access.
Mary Greeley Medical Center Secures Grant for Advanced Opioid Security System
Mary Greeley Medical Center received funding to implement the NarcBox security system, representing a significant step in combating opioid theft and misuse through enhanced tracking and security measures.
Nutriband Partners with Brand Institute to Develop Global Brand Identity for Abuse-Deterrent Fentanyl Patch
Nutriband Inc. has partnered with Brand Institute to create the worldwide commercial brand identity for AVERSA FENTANYL, positioning the product to potentially become the world's first abuse-deterrent opioid patch with significant implications for addressing the opioid crisis.
Nutriband Showcases AVERSA™ Abuse-Deterrent Technology Addressing Opioid Crisis at Emerging Growth Conference
Nutriband Inc. presented its AVERSA™ abuse-deterrent transdermal technology at the August 2025 Emerging Growth Conference, projecting peak annual sales of $200 million for its fentanyl patch upon FDA approval with potential to exceed $800 million, offering a critical solution to the ongoing opioid epidemic.
Nutriband Inc. Advances in Opioid Safety with AVERSA(TM) Fentanyl Milestone
Nutriband Inc. achieves a significant milestone in the development of AVERSA(TM) Fentanyl, an abuse-deterrent opioid, marking progress in addressing the global opioid crisis.
Nutriband Inc. Advances Aversa Fentanyl to Commercial Manufacturing Scale with Kindeva
Nutriband Inc. and Kindeva have successfully scaled up the commercial manufacturing process for Aversa Fentanyl, an abuse-deterrent opioid patch, marking a significant step towards addressing the opioid crisis with innovative technology.
Nutriband Inc. Reports Significant Revenue Growth and Advances in AVERSA Fentanyl Development
Nutriband Inc. showcases a 63% year-over-year revenue increase in Q1 2025 and progresses in developing AVERSA Fentanyl, aiming to introduce the first abuse-deterrent opioid patch globally.
Nutriband Inc. to Showcase Innovations at Noble Capital Markets Emerging Growth Virtual Conference
Nutriband Inc. (NASDAQ: NTRB) is set to present at the Noble Capital Markets Emerging Growth Virtual Equity Conference, highlighting its advancements in abuse-deterrent transdermal pharmaceutical products, a critical step in addressing the opioid crisis.